ClinicalTrials.gg
CompletedNCT03888716Updated Oct 20, 2021

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

A Phase 1 interventional study of KL1333 and Placebo Oral Tablet in Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies and MELAS Syndrome, sponsored by Abliva AB. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-20.

Primary conditionMELAS SyndromeRegistry: Mitochondrial DiseasesReclassifiedWhy we changed it
Registry
Mitochondrial Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
MELAS Syndrome
Why
  1. The study's listed conditions name MELAS Syndrome, a narrower term within Mitochondrial Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Abliva AB (part of Pharming Group N.V.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.

Read the detailed description

Part A: Eight healthy subjects will be studied in a single cohort (Group A1). Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will participate in 2 treatment periods, fasting or after consuming a standard high-fat breakfast. For each treatment period, subjects will reside at the Phase I clinical site from Days 1 to 3 (48 hours postdose). Subjects will return to the clinical site for outpatient visits on Days 4 and 5. There will be at least a 10 day washout between doses Additional single-dose cohorts may be enrolled based on data obtained from either Parts A or B.

Part B: Sixteen healthy subjects will be studied in 2 cohorts (Groups B1 and B2), with each cohort consisting of 8 subjects. Following review of safety, tolerability, and PK data, up to 3 additional dose cohorts of healthy subjects may be added to further explore the PK, safety, and tolerability of KL1333. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. All subjects will participate in 1 treatment period and will reside at the Phase I clinical site from Days -1 to 12 (48 hours post final dose). Subjects will return to the clinical site for outpatient visits on Days 13 and 14. On Day 1, 6 subjects will be randomised to receive KL1333 and 2 subjects will be randomised to receive placebo. Subjects will return for a Follow-up visit on Day 15, 5 days after their final dose.

Part C: A total of 8 patients diagnosed with any mitochondrial disease will be enrolled in this part of the study. Part C may start after the dose selection conference has been completed for the final cohort of Part B, at a daily dose no higher than the highest well-tolerated dose in Part B. Potential study patients will be screened to assess their eligibility to enter the study within 35 days prior to the first dose administration. Patients will reside at the clinical site from Days -1 to 2 and Days 10 to 11 and return to the clinical site for outpatient visits on Days 4 and 8. It is planned for patients to receive study drug once daily on Days 1 to 10. Patients will return for a Follow-up visit on Day 15, 5 days after their final dose.

02

Conditions studied

  • Mitochondrial Diseases
  • Mitochondrial Respiratory Chain Deficiencies
  • MELAS Syndrome
  • Mitochondrial Myopathies

Browse trials for

Keywords

  • Mitochondrial Diseases
  • Mitochondrial Respiratory Chain Deficiencies
  • MELAS Syndrome
  • Mitochondrial Myopathies
  • Kearns-Sayre Syndrome
  • Ophthalmoplegia, Chronic Progressive External
03

In context

MELAS Syndrome Reclassified

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's enrollment of 72 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Abliva AB is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted before Abliva AB became part of Pharming Group N.V..

Compared within MELAS Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mitochondrial Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy subjects and patients with mitochondrial disease must satisfy all of the following criteria at the Screening visit unless otherwise stated:

  1. Females will not be pregnant or lactating, and females of and males will agree to use .
  2. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  3. Able to perform all protocol-specified assessments and comply with the study visit schedule.

    Additional inclusion criteria for healthy subjects:

  4. Males or females, of any race, between 18 and 65 years of age, inclusive.
  5. Weight ≥50 kg and between 18.0 and 32.0 kg/m2, inclusive.
  6. In good health, determined by no findings from medical history, physical examination, 12 lead , vital signs measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening and Check in as assessed by the Investigator.

    Additional inclusion criteria for patients with mitochondrial disease:

  7. Males or females, of any race, between 18 and 75 years of age, inclusive.
  8. Body mass index between 15.0 and 32.0 kg/m2, inclusive.
  9. Any mitochondrial disease that has been genetically confirmed.
  10. Clinically stable, apart from symptoms associated with the diagnosis of mitochondrial disease, as determined by medical history, physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations at Screening and Check-in as assessed by the Investigator.

Exclusion criteria

Exclusion Criteria (selected):

Healthy subjects and patients with mitochondrial disease will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

  1. History of significant , intolerance, or allergy to any drug compound, food, or other substance, including KL1333 or its , unless approved by the Investigator.
  2. History of gastroesophageal reflux disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes.
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs including cholecystectomy (uncomplicated appendectomy and hernia repair will be allowed).
  4. History of of any organ system other than localised basal cell carcinoma of the skin, treated or untreated, within 5 years prior to Screening, regardless of whether there is evidence of local recurrence or .
  5. History of illness (except for mitochondrial disease in the patients in Part C) or surgery within 4 weeks prior to Screening, as determined by the Investigator.
  6. History of alcoholism or drug/chemical abuse within 2 years prior to Screening.
  7. Alcohol consumption of >28 units per week for males and >21 units per week for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  8. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check in.
  9. Positive hepatitis panel and/or positive test

Additional exclusion criteria for patients with mitochondrial disease:

  1. Use of idebenone or medications (prescription or nonprescription) that have effects on metabolism or unknown binding sites (eg, vitamin E, co-enzyme 10, arginine) within 35 days or 5 half-lives, whichever is longer, prior to the first dose.
  2. Use of prescription drugs within 14 days prior to dosing, with the exception of established therapy for mitochondrial disease and the treatment of associated disorders that has been stable for at least 7 days prior to the first dose, as approved by the Medical Monitor and Investigator, in consultation with the Sponsor.
  3. Uncontrolled diabetes mellitus, as determined by the Investigator. \<45 mL/min as calculated by the Cockcroft-Gault equation
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    KL1333

    25 and 100 mg KL1333 encapsulated tablets for daily oral dosing

    Drug: KL1333

  • Placebo comparator
    Matching placebo

    25 and 100 mg KL placebo encapsulated tablets for daily oral dosing

    Drug: Placebo Oral Tablet

Interventions

  • DrugKL1333

    25 and 100 mg KL1333 encapsulated tablets

  • DrugPlacebo Oral Tablet

    25 and 100 mg placebo encapsulated tablets

06

What researchers measure

Primary outcomes

  1. Safety: incidence and severity of AEs

    Time frame: Day 15

  2. Safety: incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results

    Time frame: Day 15

  3. Safety: 12 lead ECG parameters

    Time frame: Day 15

  4. Safety: Number of participants with clinically significant abnormal vital signs measurements

    Time frame: Day 15

  5. Safety: Number of participants with clinically significant abnormal physical examinations

    Time frame: Day 15

Secondary outcomes

  1. PK: area under the curve, AUC0 ∞

    Time frame: Day 1

  2. PK: AUC over a dosing interval (AUC0 τ)

    Time frame: Days 1 and 10

  3. PK: temporal change parameter (TCP; AUC0 τ/AUC0-∞)

    Time frame: Days 1 and 10

  4. PK: Cmax

    Time frame: Day 1

  5. PK: time of the Cmax (Tmax)

    Time frame: Day 1

  6. PK: minimum observed plasma concentration (Cmin)

    Time frame: Days 1 and 10

  7. PK: apparent plasma terminal elimination half life (t1/2)

    Time frame: Days 1 and 10

  8. PK: mean residence time (MRT)

    Time frame: Days 1 and 10

  9. PK: apparent total plasma clearance (CL/F)

    Time frame: Days 1 and 10

  10. PK: apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Days 1 and 10

Other outcomes

  1. NAD+/NADH concentrations and ratio (part B and C)

    Biomarker

    Time frame: Days 10 and 15

  2. FGF21 and GDF15 concentrations (part B and C)

    Biomarker

    Time frame: Days 10 and 15

  3. Lactate/pyruvate concentrations and ratio (part B and C)

    Biomarker

    Time frame: Days 10 and 15

  4. Newcastle Mitochondrial Disease Adult Scale (NMDAS) (part C)

    Assessment of mitochondrial disease. The NMDAS is a validated clinical rating scale designed to capture the natural history of mitochondrial disease. The NMDAS includes 3 domains: current function, system specific involvement, and current clinical, assessed on 6-point Likert-type scale from 0 to 5, as well as a fourth section including a score for the 12-Item Short Form Survey-Version 2.

    Time frame: Day 10

  5. Clinician Global Impression (CGI) (part C)

    Assessment of illness severity, global improvement or change, and therapeutic response.The CGI is a 3-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. The CGI is rated on a 7-point Likert-type scale, with the severity of illness scale using a range of responses from 1 (normal) to 7 (amongst the most severely ill patients).

    Time frame: Day 10

  6. Patient Global Impression-Improvement (PGI-I) (part C)

    Patient reported assessment of severity of illness. The PGI-I is a patient-rated scale using a 7-point Likert-type scale, with the severity of illness scale using a range of responses from 1 (normal) to 7 (amongst the most severely ill patients). An item about the patient's worst symptom will be included in the assessment for this study.

    Time frame: Day 10

  7. Daily Fatigue Impact Severity (D-FIS) (part C)

    Assessment of fatigue. The D-FIS is a patient-rated scale developed to assess the symptom of fatigue as part of an underlying chronic disease or condition. The D-FIS includes 8 items assessed on 5-point Likert-type scale from 0 (no problem) to 4 (extreme problem).

    Time frame: Day 10

  8. Quality of Life in Neurological Disorders Fatigue Scale (Neuro-QoL Fatigue) (part C)

    Assessment of fatigue. The Neuro-QoL Fatigue is one of several scales that make up the Quality of Life in Neurological Disorders measurement system. It is a reliable and validated brief 19-item survey of fatigue, completed by the subject, with a recall period of the past 7 days. The 19 items are scored from 1 (never) to 5 (always) and consequently, Neuro-QoL Fatigue total scores range from 19 to 95, with higher scores indicating greater fatigue and greater impact of mitochondrial disease on activities.

    Time frame: Day 10

  9. 30 Second Sit-to-Stand Test (part C)

    Test

    Time frame: Day 10

07

Study locations

2 sites
  • Covance Leeds
    Leeds, West Yorkshire LS2 9LH, United Kingdom
  • UCL
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — According to EMA rules.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2021, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 25, 2019
StartActual
Mar 18, 2019
Primary completionActual
Mar 16, 2021
CompletionActual
Mar 16, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03888716
Lead sponsor
Abliva AB
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Mar 18, 2019
Primary completion
Mar 16, 2021
Completion
Mar 16, 2021
Last update
Oct 20, 2021

Study contacts

Matilda Hugerth, MSc
study director · Abliva AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Napazimone

Start the discussion